Phase 1 Type 2 diabetes trials recruiting now

All Type 2 diabetes trials, every phase

Other phases for Type 2 diabetes

Phase 1 Type 2 diabetes trials

• A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes
  NCT07032688 · Phase: Phase 1 · Ages: 18 Years to 59 Years · Sex: All (male and female) · 1 location
• A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity
  NCT07747857 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 12 locations
• A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
  NCT06937203 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 16 locations
• A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
  NCT06700538 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 7 locations
• A Food-Effect Study of CX11 in Healthy Participants
  NCT07349381 · Phase: Phase 1 · Ages: 18 Years to 45 Years · Sex: All (male and female) · 1 location
• A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
  NCT07539415 · Phase: Phase 1 · Ages: 19 Years to 64 Years · Sex: All (male and female) · 1 location
• A Phase 1, Multiple Ascending Dose Study to Evaluate HMS1005 in Participants With Type 2 Diabetes
  NCT07568678 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
  NCT06694935 · Phase: Phase 1 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 1 location
• A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
  NCT07061574 · Phase: Phase 1, Phase 2 · Ages: 9 Years to 20 Years · Sex: All (male and female) · 10 locations
• A Research Study of a New Medicine, NNC9733-0001, in Healthy Participants and Participants With Type 2 Diabetes
  NCT07270731 · Phase: Phase 1 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 1 location
• A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DM
  NCT07570992 · Phase: Phase 1 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 1 location
• A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors
  NCT07463196 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes
  NCT06945406 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
  NCT06924320 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus
  NCT07619157 · Phase: Phase 1 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 2 locations
• A Study of REGEND003 on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)
  NCT07275788 · Phase: Phase 1 · Ages: 30 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
  NCT05824975 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
  NCT07024823 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 10 locations
• A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
  NCT07723833 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 2 locations
• A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D
  NCT07702890 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
  NCT07590193 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities
  NCT05369065 · Phase: Phase 1 · Ages: 21 Years to 65 Years · Sex: All (male and female) · 3 locations
• Alpelisib Challenge Test (ACT)
  NCT07778524 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Arterial Ablation for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities
  NCT05363761 · Phase: Phase 1 · Ages: 21 Years to 65 Years · Sex: All (male and female) · 6 locations
• Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II
  NCT05702463 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Bioequivalence Study of GZR18 Injection Before and After CMC Change
  NCT07355738 · Phase: Phase 1 · Ages: 18 Years to 50 Years · Sex: Male · 1 location
• Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
  NCT05142189 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 45 locations
• Comparison Study of Insulin GZR4 With Insulin Degludec
  NCT07146347 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Denosumab for Type 1 Diabetes
  NCT06524960 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 3 locations
• Doxycycline in Type II Diabetes
  NCT06329882 · Phase: Phase 1, Phase 2 · Ages: 40 Years to 60 Years · Sex: All (male and female) · 1 location
• Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers
  NCT05610865 · Phase: Phase 1 · Ages: 20 Years to 60 Years · Sex: All (male and female) · 1 location
• Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D
  NCT06829563 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• FES Cycling With BFR in the Spinal Cord Injury Population
  NCT07588503 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Graded Insulin Suppression Test P&F
  NCT06592261 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Heat Therapy in Type 2 Diabetes
  NCT06596967 · Phase: Phase 1 · Ages: 55 Years and older · Sex: All (male and female) · 1 location
• Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes
  NCT07535307 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
  NCT04187443 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Montbretin Clinical Trial in Healthy Volunteers and Type 2 Diabetics
  NCT05826054 · Phase: Phase 1 · Ages: 19 Years to 65 Years · Sex: All (male and female) · 1 location
• Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye
  NCT02846571 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Pharmacogenetics of Response to GLP1R Agonists
  NCT05071898 · Phase: Phase 1 · Ages: 18 Years to 89 Years · Sex: All (male and female) · 1 location
• Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity
  NCT07803809 · Phase: Phase 1 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 2 locations
• Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes
  NCT07167693 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Polypill for Prevention of Cardiomyopathy
  NCT06143566 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 1 location
• SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
  NCT07053306 · Phase: Phase 1 · Ages: 30 Years to 75 Years · Sex: All (male and female) · 1 location
• SGLT2i, Pioglitazone, and Ketone Production in T2D
  NCT07053319 · Phase: Phase 1 · Ages: 30 Years to 75 Years · Sex: All (male and female) · 1 location
• SGLTi, Hepatic Glucose Production and Ketogenesis
  NCT05960656 · Phase: Phase 1 · Ages: 30 Years to 75 Years · Sex: All (male and female) · 1 location
• Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial
  NCT07396155 · Phase: Phase 1, Phase 2 · Ages: 30 Years to 65 Years · Sex: All (male and female) · 1 location
• Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus
  NCT07563699 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 1 location
• Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus
  NCT05268237 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
  NCT07399678 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
  NCT05267626 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
  NCT06562907 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 3 locations
• Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency
  NCT07385547 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 3 locations
• THC Effects on Glucose in Type 2 Diabetes
  NCT05322213 · Phase: Phase 1 · Ages: 21 Years to 70 Years · Sex: All (male and female) · 1 location
• Time Restricted Eating in Patients With Microalbuminuria
  NCT06884059 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
  NCT06578676 · Phase: Phase 1 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus
  NCT07374328 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• hUC-MSC-Exosomes for T2DM - Safety & Efficacy
  NCT07693036 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.